

Supplementary Table 2

Univariate analysis of the association of ocular and systemic factors with the number of anti-VEGF injections required over two years of Observe-and-Plan an interval-based variable-dosing regimen for neovascular age-related macular degeneration. (Full Version)

Factors		N	Mean number of anti-VEGF injections Mean \pm SD	p
	Overall	205	14.1 \pm 5.9	
	Quartiles	205	10 / 14 / 18	
Ocular baseline characteristics				
Eye	Right	100	14.1 \pm 0.6	0.97
	Left	105	14.2 \pm 0.6	
VA baseline	Per 10-letter ETDRS increase		0.14 \pm 0.02 (r = 0.04)	0.56
CNV type	Occult	91	14.5 \pm 0.6	0.27
	Minimally Classic	20	15.8 \pm 1.3	
	Predominantly Classic	56	13.7 \pm 0.8	
	RAP	37	12.9 \pm 1.0	
CNV size	Per disc area	205	0.02 \pm 0.25 (r = 0.01)	0.92
RPE detachment baseline	Present \geq 200- μ m height	57	15.4 \pm 0.8	0.054
	Absent or < 200- μ m height	148	13.6 \pm 0.5	
CRT baseline	Per 10- μ m-thickness increase	205	0.09 \pm 0.00 (r = 0.27)	0.0001*
	Per 10- μ m-thickness (corrected for study/SD-OCT machine)	205	0.10 \pm 0.003 (r = 0.22)	0.002* (0.02*)
Intraretinal cysts	Present	123	14.0 \pm 0.53	0.62
	Absent	81	14.4 \pm 0.65	
	Missing data	1		
Intraretinal cysts, foveal	Present	83	14.7 \pm 0.64	0.30
	Absent	121	13.8 \pm 0.53	
	Missing data	1		
Subretinal fluid	Present	18	14.5 \pm 0.46	0.17
	Absent	46	13.1 \pm 0.86	
	Missing data	1		
Subretinal tissue complex	Per 10- μ m-thickness increase	204	0.07 \pm 0.004 (r = 0.12)	0.10
	Per 10- μ m-thickness increase	205	-0.01 \pm 0.004 (r = -0.01)	0.85
	Missing data			
Choroidal thickness, subfoveal	Per 10- μ m-thickness increase (corrected for age and axial length)	205	0.026 \pm 0.003 (r = 0.07)	0.30 (0.24)
Reticular pseudodrusen	Present	98	14.0 \pm 0.59	0.65
	Absent	105	14.4 \pm 0.57	
	Missing data	2		
Soft drusen	Present	99	14.0 \pm 0.59	0.96
	Absent	101	14.0 \pm 0.58	
	Missing data	3		
Hyperpigmentation	Present	146	14.0 \pm 0.49	0.91
	Absent	52	14.1 \pm 0.8	
Depigmentation	Present	109	13.3 \pm 0.56	0.06
	Absent	89	14.9 \pm 0.62	
GA at baseline	Present	43	13.3 \pm 0.89	0.27
	Absent	162	14.4 \pm 0.46	
Epiretinal membrane	Present	16	14.1 \pm 1.47	0.96
	Absent	189	14.1 \pm 0.43	

Vitreomacular adhesion	Present	44	13.8 ± 0.88	0.62
	Absent	161	14.2 ± 0.46	
Ocular follow-up characteristics				
Study	Aflibercept/OCT Spectralis/Team 2	100	15.2 ± 0.58	0.01*
	Ranibizumab/OCT Cirrus/Team 1	105	13.1 ± 0.56	
VA Month-3	Per 10-ETDRS letters	205	-0.05 ± 0.03 (r = -0.01)	0.87
VA change to Month-3	Per 10 ETDRS letters	205	-0.05 ± 0.04 (r = -0.08)	0.24
Type of fluid at Month-3	Subretinal + intraretinal fluid	25	19.5 ± 1.04	<0.0001*
	Subretinal fluid only	25	16.9 ± 1.04	
	Intraretinal fluid only	91	14.1 ± 0.55	
	No subretinal or intraretinal fluid	64	11.0 ± 0.65	
Subretinal fluid at Month-3	Present	50	18.2 ± 0.76	<0.0001*
	Absent	155	12.8 ± 0.43	
Intraretinal fluid at Month-3	Present	116	15.3 ± 0.53	0.001*
	Absent	89	12.6 ± 0.61	
RPE detachment at Month-3	Per 10-µm-thickness	205	0.12 ± 0.003 (r 0.27)	< 0.0001*
CRT at Month-3	Per 10-µm-thickness (corrected for study/OCT machine)	205	0.36 ± 0.006 (r = 0.38)	< 0.0001*
CRT change to Month-3	Per 10-µm-thickness increase	205	-0.02 ± 0.003 (r = -0.04)	0.59
Systemic characteristics				
Age (years)	Per 10-yr increase	205	-0.30 ± 0.06 (r = -0.04)	0.59
Sex	Female	126	14.3 ± 0.5	0.47
	Male	59	13.6 ± 0.8	
BMI (kg/m ²)	Per unit	189	-0.13 ± 0.09 (r = -0.11)	0.12
Arterial hypertension	Yes	102	13.8 ± 0.58	0.52
	No	101	14.3 ± 0.58	
	Missing data	2		
Cardiovascular disorders	Present	53	14.9 ± 0.80	0.23
	Absent	150	13.8 ± 0.48	
	Missing data	22		
Smoking history	Positive	44	14.5 ± 0.88	0.69
	Negative	151	14.1 ± 0.47	
	Missing data	10		
Antidepressant medication	Yes	19	13.8 ± 0.43	0.12
	No	184	16.0 ± 1.33	
	Missing data	2		

SD = standard deviation; VA = visual acuity; ETDRS = early treatment diabetic retinopathy study; CNV = choroidal neovascularisation; RAP = retinal angiomatous proliferation; r = correlation coefficient; RPE = retinal pigment epithelium; CRT = central retinal thickness; GA = geographic atrophy; BMI = body mass index; *p < 0.05